Textbook of Personalized Medicine - Second Edition [2015]

237

Table 10.3 Marketed anticancer personalized medicines

Medicine/company Target

Companion diagnostic
(company) Indication
Cetuximab (Erbitux)/
Merck KGaA

EGFR TheraScreen K-RAS

Mutation Kit (DxS/

QIAGEN) to exclude

non-responders

Squamous cell
carcinoma (head and
neck), colorectal
carcinoma
Crizotinib (Xalkori)/
Pfi zer

ALK ALK Break Apart FISH

Probe (Vysis) to detect

rearrangements of the

ALK gene

Non-small cell lung

cancer

Dasatinib (Sprycel ® )/
Bristol-Myers-Squibb

BCL- ABL Not required Chronic myelogenous
leukemia
Erlotinib (Tarceva)/Roche EGFR Cobas EGFR Mutation Test
(Roche)

Non small cell lung
cancer
Gefi tinib (Iressa)/Astra
Zeneca

EGFR EGFR mutation test (DxS/

QIAGEN) to identify

patients most likely to

benefi t

Lung adenocarcinoma

Imatinib (Glivec)/
Novartis

BCL-

ABL,

KIT

No companion test for

leukemia, but c-KIT

immunoassay for patients

with gastrointestinal

stromal tumors

Chronic myelogenous

leukemia

Gastrointestinal stromal

tumor

Nilotinib (Tarceva)/
Novartis

BCL- ABL Not required Chronic myelogenous
leukemia
Panitumumab (Vectibix )/
Amgen

KRAS Home-brew tests for the

K-ras mutation

Colorectal cancer

Sorafenib (Nexavar)/
Bayer Healthcare

RAF,

VEGF,

KIT,

FLT3

Measuring levels of

biomarkers, VEGF and

KDR (VEGFR2), to

determine response to

sorafenib treatment

(Bayer)

Renal cell carcinoma

Liver cancer

Trastuzumab (Herceptin)/
Roche

HER2 PathVysion HER-2 breast

cancer test kit (Vysis/

Abbott)

Breast carcinoma

Verumafenib (Zelboraf)/
Roche

BRAF Multiplex PCR-based

diagnostic for the BRAF

V600E gene (Roche)

Melanoma

© Jain PharmaBiotech
ALK anaplastic lymphoma kinase

Functional Antibody-Based Therapies

Functional antibodies are biological molecules that trigger death in cancer cells but
not healthy cells. Functional antibodies target molecules carried on the outside of a
cancer cell membrane known as antigens. These cell surface proteins are decorated
with sugar chains in distinctive arrangements that can be used as targets for

Immunotherapy of Cancer